NO2957292T3 - - Google Patents

Info

Publication number
NO2957292T3
NO2957292T3 NO15170572A NO15170572A NO2957292T3 NO 2957292 T3 NO2957292 T3 NO 2957292T3 NO 15170572 A NO15170572 A NO 15170572A NO 15170572 A NO15170572 A NO 15170572A NO 2957292 T3 NO2957292 T3 NO 2957292T3
Authority
NO
Norway
Application number
NO15170572A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901461A external-priority patent/AU2008901461A0/en
Application filed filed Critical
Publication of NO2957292T3 publication Critical patent/NO2957292T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0616—Skin treatment other than tanning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
NO15170572A 2008-03-27 2009-03-27 NO2957292T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008901461A AU2008901461A0 (en) 2008-03-27 Therapy for vitiligo
EP09726233.1A EP2278992B1 (fr) 2008-03-27 2009-03-27 Therapie pour le vitiligo

Publications (1)

Publication Number Publication Date
NO2957292T3 true NO2957292T3 (fr) 2018-05-12

Family

ID=41017103

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15170572A NO2957292T3 (fr) 2008-03-27 2009-03-27

Country Status (13)

Country Link
US (3) US20110130705A1 (fr)
EP (2) EP2278992B1 (fr)
CA (1) CA2719707C (fr)
DK (1) DK2957292T3 (fr)
ES (2) ES2550160T3 (fr)
HR (1) HRP20180069T1 (fr)
HU (1) HUE038611T2 (fr)
NO (1) NO2957292T3 (fr)
NZ (1) NZ588213A (fr)
PL (1) PL2957292T3 (fr)
PT (1) PT2957292T (fr)
SI (1) SI2957292T1 (fr)
WO (1) WO2009118191A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130705A1 (en) 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
CA2822746A1 (fr) * 2009-12-21 2011-06-30 Sarah Bacus Compositions et methodes de traitement du vitiligo
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
WO2013024487A1 (fr) 2011-08-16 2013-02-21 SALAFIA Elizabeth Composition anti-vitiligo
FR2984167B1 (fr) * 2011-12-16 2014-01-17 Galderma Res & Dev Association d'un agoniste des recepteurs des prostaglandines et d'un agoniste du recepteur mc1r pour le traitement et/ou la prevention de desordres de la pigmentation
WO2013135880A1 (fr) * 2012-03-15 2013-09-19 Galderma Research & Development Combinaison d'un agoniste du récepteur mc1r et d'uvb dans le traitement et/ou la prévention de troubles de la pigmentation
WO2015063099A1 (fr) * 2013-10-28 2015-05-07 Clinuvel Ag Analogues de l'alpha-msh destinés à être utilisés dans le traitement de la maladie de hailey-hailey
WO2015063102A1 (fr) * 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh pour une utilisation dans le traitement de la maladie de hailey-hailey
EP2875806A1 (fr) * 2013-11-20 2015-05-27 Infinitec Activos, S.L. Capsules ciblées pour l'administration d'agents de blanchiment de la peau
WO2023111264A1 (fr) 2021-12-17 2023-06-22 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Exposition modérée aux uv-b en lieu et place d'une restriction alimentaire

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
ATE84420T1 (de) * 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
DE3851002T2 (de) 1987-05-22 1995-02-02 University Patents Inc Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US6251100B1 (en) 1993-09-24 2001-06-26 Transmedica International, Inc. Laser assisted topical anesthetic permeation
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU4004699A (en) 1998-05-15 1999-12-06 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
NZ534450A (en) * 2002-02-26 2008-08-29 Arizona Board Of Regents Of Be Method of stimulation of melanin production and induction of skin tanning comprising administering alpha-MSH and exposing skin to UV irradiation
US20040009170A1 (en) 2002-07-10 2004-01-15 Stafano Gatti Alpha-melanocyte stimulating hormone peptides protection in organ transplantation
NZ582130A (en) 2004-08-04 2011-11-25 Clinuvel Pharmaceuticals Ltd Methods of inducing melanogenesis in a subject
CA2575988C (fr) * 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Procede de production de systemes d'administration, et systemes d'administration
EP1812034A4 (fr) * 2004-10-08 2009-07-29 Clinuvel Pharmaceuticals Ltd Prépaprations et méthodes permettant d'induire la mélanogenèse chez un sujet
CN101511380B (zh) 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
NZ575133A (en) * 2006-08-31 2011-11-25 Clinuvel Pharmaceuticals Ltd Method of treatment of photodermatoses using an alpha-msh analogue
FR2907681B1 (fr) * 2006-10-26 2012-10-19 Vincience Composition pharmaceutique et/ou cosmetique contenant des polypeptides ou des peptides.
FR2907682B1 (fr) * 2006-10-26 2012-12-07 Vincience Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
US20110130705A1 (en) 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo

Also Published As

Publication number Publication date
AU2009228664A1 (en) 2009-10-01
PT2957292T (pt) 2018-02-09
EP2278992B1 (fr) 2015-07-22
HRP20180069T1 (hr) 2018-04-20
US11622994B2 (en) 2023-04-11
US20180008676A1 (en) 2018-01-11
US9801924B2 (en) 2017-10-31
ES2656131T3 (es) 2018-02-23
US20130203670A1 (en) 2013-08-08
ES2550160T3 (es) 2015-11-04
EP2278992A2 (fr) 2011-02-02
WO2009118191A2 (fr) 2009-10-01
SI2957292T1 (en) 2018-04-30
EP2957292A1 (fr) 2015-12-23
US20110130705A1 (en) 2011-06-02
HUE038611T2 (hu) 2018-10-29
EP2957292B1 (fr) 2017-12-13
DK2957292T3 (en) 2018-01-22
PL2957292T3 (pl) 2018-04-30
CA2719707C (fr) 2018-12-04
CA2719707A1 (fr) 2009-10-01
NZ588213A (en) 2012-10-26
WO2009118191A3 (fr) 2009-12-03

Similar Documents

Publication Publication Date Title
BR112016019572A2 (fr)
BRPI0917573A2 (fr)
BRPI0918697A2 (fr)
BRPI0917525A2 (fr)
BRPI0920750A2 (fr)
BRPI0919470A2 (fr)
BRPI0922455A2 (fr)
BRPI0917618A8 (fr)
BRPI0923734A2 (fr)
BRPI0914750A2 (fr)
BRPI0922669A2 (fr)
BRPI0919811A2 (fr)
BRPI0920914A2 (fr)
BRPI0922550A2 (fr)
BRPI0914852A2 (fr)
NO2957292T3 (fr)
CH2347250H2 (fr)
BRPI0914820A2 (fr)
AR073287B1 (fr)
BRPI0919477A2 (fr)
BRPI0923127A (fr)
BRPI0923137A2 (fr)
BRMU8803485U8 (fr)
CN300891520S (zh) 瓶贴(13)
CN300880412S (zh) 地毯(29-33)